Drug Profile
Syn 2002
Alternative Names: Dox-SynB1; Dox-SynB3; Doxorubicin peptide conjugate - Synt:em; Syn2002; Vectorised doxorubicin - Synt:emLatest Information Update: 20 Jan 2011
Price :
$50
*
At a glance
- Originator Synt:em
- Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors; Reactive oxygen species stimulants; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Jan 2011 No development reported - Preclinical for Cancer in France (unspecified route)
- 23 Jun 2004 Syn 2002 is available for licensing (http://www.syntem.com)
- 10 Jul 2003 Preclinical trials in Cancer in France (unspecified route)